Evidence map›Paper›PMID 32777641›Full record

ArticleBioorganic chemistry2020

Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors.

Xuwei Shao, Steven Pak, Uday Kiran Velagapudi, Shruthi Gobbooru, Sai Shilpa Kommaraju, Woon-Kai Low, Gopal Subramaniam, Sanjai Kumar Pathak, Tanaji T Talele

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xuwei ShaoDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Steven PakDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Uday Kiran VelagapudiDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Shruthi GobbooruDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Sai Shilpa KommarajuDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Woon-Kai LowDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Gopal SubramaniamChemistry and Biochemistry Department, Queens College of the City University of New York, 65-30 Kissena Blvd., Flushing, NY 11367, USA.
Sanjai Kumar PathakChemistry and Biochemistry Department, Queens College of the City University of New York, 65-30 Kissena Blvd., Flushing, NY 11367, USA; Chemistry Doctoral Program, Biochemistry Doctoral Program, The Graduate Center of the City University of New York, 365 5th Ave, New York, NY 10016, USA. Electronic address: Sanjai.Kumar@qc.cuny.edu.
Tanaji T TaleleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA. Electronic address: talelet@stjohns.edu.
St. John's University · USQueens College, CUNY · USThe Graduate Center, CUNY · US

Funding

Development of PARP-Isoform Selective Inhibitory Chemical ProbesSC3GM131971 · NIGMS · ST. JOHN'S UNIVERSITY · PI TALELE, TANAJI T · 2019 to 2022
$492k
Development of Light-activatable Probes and Dual-Action Inhibitors of Nek2 KinaseR15CA243109 · NCI · QUEENS COLLEGE · PI PATHAK, SANJAI KUMAR · 2019 to 2019
$381k
NIGMS NIH HHS SC3 GM131971
6 · The paper itself

Abstract

Poly(ADP-ribose) polymerase 1 (PARP1), a widely explored anticancer drug target, plays an important role in single-strand DNA break repair processes. High-throughput virtual screening (HTVS) of a Maybridge small molecule library using the PARP1-benzimidazole-4-carboxamide co-crystal structure and pharmacophore model led to the identification of eleven compounds. These compounds were evaluated using recombinant PARP1 enzyme assay that resulted in the acquisition of three PARP1 inhibitors: 3 (IC

Indexed as

DioxinsHigh-Throughput Screening AssaysHumansMolecular Docking SimulationPoly(ADP-ribose) Polymerase InhibitorsStructure-Activity RelationshipDioxinsPoly(ADP-ribose) Polymerase Inhibitors1,4-benzodioxine1,4-benzoxazin-3-oneKnoevenagel condensationPARP1Virtual screening

Identifiers

PMID32777641
PMCPMC8142146
OpenAlexW3039354167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.